Clinical trials in Guinea
46 studies list at least one site in Guinea. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-08-27.
Status
- Completed
- 30
- Status unknown
- 8
- Recruiting
- 4
- Not yet recruiting
- 2
- Active, not recruiting
- 1
- Terminated
- 1
Phase
- Phase 2
- 15
- Phase 3
- 14
- Phase 4
- 5
- Phase 1
- 1
Most studied here
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (7) · ANRS, Emerging Infectious Diseases (6) · Drugs for Neglected Diseases (4) · Institut de Recherche pour le Developpement (3) · McGill University (2) · Centre National de Formation et de Recherche en Sante Rurale (2) · Institut National de la Santé Et de la Recherche Médicale, France (2) · Institute for Research and Development of Medicinal and Food Plants of Guinea (2)
Studies
Recruiting first, then most recently updated. Showing 46 of 46 — search for more.
- An International Observational Study of Adults With Acute InfectionRecruitingNCT07069400
- Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis TreatmentRecruitingNCT07477119Phase 4
- Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : GuineaNot yet recruitingNCT07534267
- Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOPRecruitingNCT04794296
- EBOla Post-Exposure ProphylaxisNot yet recruitingNCT06841614Phase 3
- Febrile Illness in GuineaRecruitingNCT06122259
- Investigation of Immune Amnesia Following Measles Infection in Select African RegionsCompletedNCT06153979
- Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric PatientsCompletedNCT05433350Phase 2/3
- Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune SuppressionCompletedNCT04738812Phase 3
- International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)CompletedNCT05096091
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.CompletedNCT03923725Phase 3
- Efficacy of Favipiravir Against Ebola (JIKI)CompletedNCT02329054Phase 2
- Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. GambienseCompletedNCT03087955Phase 2/3
- A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in InfantsCompletedNCT03929757Phase 2
- Safety and Tolerability Study of Acoziborole in g-HAT Seropositive SubjectsCompletedNCT05256017Phase 2/3
- Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the SemenTerminatedNCT02739477Phase 2
- Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any StageCompletedNCT03025789Phase 3
- Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, GuineaCompletedNCT04969913
- Partnership for Research on Ebola VACcinationsCompletedNCT02876328Phase 2
- Prospective Evaluation of the Specificity of Serological Tests for Human African TrypanosomiasisCompletedNCT05466630Not applicable
- Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in GuineaActive, not recruitingNCT05409300Phase 2
- Malaria Prevalence Around Maferinyah, GuineaCompletedNCT04105855
- A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary TuberculosisCompletedNCT02581527Phase 3
- Dolutegravir and Darunavir Evaluation in Adults Failing TherapyStatus unknownNCT03017872Phase 4
- DIAgnostics for Multidrug Resistant Tuberculosis in AfricaCompletedNCT03303963
- Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 InfectionStatus unknownNCT04920838Phase 2/3
- GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in SemenCompletedNCT02818582Phase 2
- Prophylaxis Vaccine Antibodies EbolaStatus unknownNCT04822376Phase 2
- Africa COVID-19 Vaccine HesitancyCompletedNCT04912284
- COVID-19 STAndard of Care in Sub-Saharan AfricaCompletedNCT04885543
- Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case DetectionCompletedNCT03356665Not applicable
- International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-CombiCompletedNCT03072030Phase 4
- Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 PatientsStatus unknownNCT04501965Phase 2
- Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 PatientsStatus unknownNCT04502342Phase 2
- HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV ExposureCompletedNCT03642704Phase 4
- Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in GuineaCompletedNCT02342171Phase 2/3
- Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola InfectionCompletedNCT02363322Phase 1/2
- A Survey of Hospitalizations in Cardiology Units in Sub-Saharan AfricaStatus unknownNCT03231449
- Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectivenessCompletedNCT00931736Phase 3
- Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)CompletedNCT00170209Phase 3
- Recurrence and Pregnancy Post-repair of Obstetric Fistula in GuineaCompletedNCT02686957
- Improving Access to HbA1c in Sub Saharan AfricaCompletedNCT01460095Not applicable
- Non-inferiority of Short-term Catheterization Following Fistula Repair SurgeryCompletedNCT01428830Not applicable
- Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary TuberculosisStatus unknownNCT00216333Phase 4
- Study of the Management of Vaginal Discharge in West African Using Single Dose TreatmentsCompletedNCT00313131Phase 3
- A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary TuberculosisStatus unknownNCT00216385Phase 3